Recursion Pharmaceuticals (RXRX) Leases: 2022-2025
Historic Leases for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Sep 2025 value amounting to $47.8 million.
- Recursion Pharmaceuticals' Leases fell 0.15% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year decrease of 0.15%. This contributed to the annual value of $65.9 million for FY2024, which is 95.70% up from last year.
- According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Leases is $47.8 million, which was down 4.99% from $50.3 million recorded in Q2 2025.
- Recursion Pharmaceuticals' Leases' 5-year high stood at $65.9 million during Q4 2024, with a 5-year trough of $33.3 million in Q4 2022.
- In the last 3 years, Recursion Pharmaceuticals' Leases had a median value of $44.1 million in 2024 and averaged $43.9 million.
- As far as peak fluctuations go, Recursion Pharmaceuticals' Leases skyrocketed by 95.70% in 2024, and later declined by 0.15% in 2025.
- Quarterly analysis of 4 years shows Recursion Pharmaceuticals' Leases stood at $33.3 million in 2022, then climbed by 1.23% to $33.7 million in 2023, then surged by 95.70% to $65.9 million in 2024, then decreased by 0.15% to $47.8 million in 2025.
- Its Leases stands at $47.8 million for Q3 2025, versus $50.3 million for Q2 2025 and $53.2 million for Q1 2025.